Eli Lilly — Valuation, Funding & Investors

We're still building this profile — here is what Pulse has covered.

Recent changes

Jun 30, 2026Jun 30, 2026Invested in Flare Therapeutics (Series C, $85M) GlobeNewswire

Latest Pulse

Jul 10, 2026Doudna-Founded Scribe Therapeutics Files S-1/A for Nasdaq IPOScribe Therapeutics, the CRISPR biotech co-founded by Nobel laureate Jennifer Doudna, amended its S-1 to list on Nasdaq under ticker SCTX, backed by more than $180 million in Sanofi and Eli Lilly partnership payments.→

Coverage Timeline

newest first

Jul 10, 2026IPODoudna-Founded Scribe Therapeutics Files S-1/A for Nasdaq IPO$180M+ partnership payments→

All Coverage

IPO· Jul 10, 2026

Doudna-Founded Scribe Therapeutics Files S-1/A for Nasdaq IPO

IPO$180M+ partnership payments

Doudna-Founded Scribe Therapeutics Files S-1/A for Nasdaq IPO

Scribe Therapeutics, the CRISPR biotech co-founded by Nobel laureate Jennifer Doudna, amended its S-1 to list on Nasdaq under ticker SCTX, backed by more than $180 million in Sanofi and Eli Lilly partnership payments.

Jul 10, 2026

Related Companies

Same sector

Attovia Therapeutics Apnimed Braveheart Bio Latigo Biotherapeutics Scribe Therapeutics